Combining statins with amlodipine to treat primary aldosteronism
A Prospective, Multi-center, Randomized Trial to Compare Statin Combined with CCB to MRA Combined with CCB in Primary Aldosteronism Treatment
This study is testing if combining statins with amlodipine can help people with primary aldosteronism manage their condition better.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 180 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Third Military Medical University Academic / other |
| Locations | 1 site (Chongqing, Chongqing Municipality) |
| Trial ID | NCT06523465 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the effectiveness of combining statins with amlodipine in treating patients with primary aldosteronism. Participants will be randomly assigned to one of three treatment groups: one receiving statin and amlodipine, another receiving statin, spironolactone, and amlodipine, and the last receiving amlodipine and spironolactone. The study will monitor changes in plasma aldosterone levels, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risks associated with these treatments.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with primary aldosteronism.
Not a fit: Patients with allergies to the study drugs, pregnancy, severe liver or kidney dysfunction, or mental illness may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve treatment options and cardiovascular outcomes for patients with primary aldosteronism.
How similar studies have performed: While there is limited information on similar studies, the combination of these medications has shown promise in managing hypertension and related conditions.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis of primary aldosteronism Exclusion Criteria: * Allergy to drugs in this study * Pregnancy * Severe liver and kidney dysfunction * Mental illness
Where this trial is running
Chongqing, Chongqing Municipality
- No. 10 Changjiang River Branch, Yuzhong District，Chongqing, China — Chongqing, Chongqing Municipality, China (Recruiting)
Study contacts
- Study coordinator: sun fang
- Email: sun_fang2007@163.com
- Phone: +862368729587
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.